Modified release oral contraceptive composition
The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.
1. An oral contraceptive composition, in the form of a tablet, wherein the tablet comprises:
(a) 2 mg of 17α-cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest, DNG);
(b) 0.02 mg of 17α-ethinylestradiol (ethynyl estradiol, EE); and,
(c) 20% to 60% w/w of a polymeric matrix forming agent based on a total weight of the composition,
wherein:
the 0.02 mg of EE is formulated with a controlled release material comprising the polymeric matrix forming agent, such that all of the EE in the contraceptive composition is subject to extended release;
the DNG and the EE are formulated such that, when the composition is subjected to an in vitro dissolution test according to USP1 (baskets) method using 900 mL of water at 37° C. (=0.5° C.) at a stirring rate of 75 rpm, the DNG and the EE, respectively, exhibit a dissolution profile such that:
no more than 20% of the EE initially present in the composition is dissolved within 0.5 hour, and
between 30% and 60% of the DNG initially present in the composition, and between 30% and 60% of the EE initially present in the composition, is dissolved within 2 hours; and
the extended release of the DNG and the EE occur at rates that are independent of pH.
2. The contraceptive composition of claim 1 , wherein after once daily oral administration to a human premenopausal female under fasting conditions for 7 days, the oral contraceptive composition provides:
a Cmax of EE ranging from 60 pg/mL to 65 pg/mL; and
a Cmax of DNG ranging from 55 ng/mL to 60 ng/mL.
3. The contraceptive composition of claim 1 , wherein after once daily oral administration to a human premenopausal female under fasting conditions for 7 days, the oral contraceptive composition provides:
a Tmax of EE ranging from 3.5 hours to 4.0 hours; and
a Tmax of DNG ranging from 3.5 hours to 4.0 hours.
4. The contraceptive composition of claim 1 , wherein after once daily oral administration to a human premenopausal female under fasting conditions for 7 days, the oral contraceptive composition provides:
an AUC 0-24hr of EE ranging from 680 pgxh/mL to 710 pgxh/mL; and
an AUC 0-24hr of DNG ranging from 710 ngxh/mL to 740 ngxh/mL.
5. The contraceptive composition of claim 1 , wherein after once daily oral administration to a human premenopausal female under fasting conditions for 7 days, the oral contraceptive composition provides:
a Cmax of EE ranging from 60 μg/mL to 65 μg/mL;
a Tmax of EE ranging from 3.5 hours to 4.0 hours;
an AUC 0-24hr of EE ranging from 680 pgxh/mL to 710 pgxh/mL;
a Cmax of DNG ranging from 55 ng/ml to 60 ng/mL;
a Tmax of DNG ranging from 3.5 hours to 4.0 hours; and
an AUC 0-24hr of DNG ranging from 710 ngxh/mL to 740 ngxh/mL.
6. The contraceptive composition according to claim 1 , wherein when the composition is subjected to an in vitro dissolution test according to USP1 (baskets) method using 900 mL of water at 37° C. (±0.5° C.) at a stirring rate of 75 rpm, the DNG and the EE, respectively, exhibit a dissolution profile such that no more than 20% of the DNG initially present in the composition, and no more than 20% of the EE initially present in the composition, is dissolved within 0.5 hour.
7. The oral contraceptive composition of claim 1 , wherein the tablet comprises 30-60% w/w of the polymeric matrix forming agent.
8. The oral contraceptive composition of claim 1 , wherein the tablet further comprises:
30-60% w/w of a diluent;
1-10% w/w of a binder; and
0-5% w/w of a lubricant.
9. The oral contraceptive composition of claim 7 , wherein the tablet comprises:
2 mg of the DNG;
0.02 mg of the EE;
35-45% w/w of a lactose based on the total weight of the composition;
45-55% w/w of a hydroxypropyl methylcellulose (HPMC) based on a total weight of the composition;
2-7% w/w of a povidone based on the total weight of the composition; and
1-3% w/w of a stearate based on the total weight of the composition.
10. The contraceptive composition according to claim 1 , wherein when the composition is subjected to an in vitro dissolution test according to USP1 (baskets) method using 900 mL of water at 37° C. (±0.5° C.) at a stirring rate of 75 rpm, the DNG and the EE, respectively, exhibit a dissolution profile wherein at least 70% of the DNG and at least 70% of the EE initially present in the composition is dissolved within 8 hours.
11. The contraceptive composition according to claim 1 , wherein when the composition is subjected to an in vitro dissolution test according to USP1 (baskets) method using 900 mL of water at 37° C. (±0.5° C.) at a stirring rate of 75 rpm, the DNG and the EE, respectively, exhibit a dissolution profile wherein:
(i) no more than 25% of the DNG and no more than 25% of the EE initially present in the composition is dissolved within 1 hour;
(ii) between 30% and 60% of the DNG and between 30% and 60% of the EE initially present in the composition is dissolved within 2 hours; and
(iii) at least 70% of the DNG and at least 70% of the EE initially present in the composition is dissolved within 8 hours.
12. The contraceptive composition according to claim 1 , wherein when the composition is subjected to an in vitro dissolution test according to USP1 (baskets) method using 900 mL of water at 37° C. (±0.5° C.) at a stirring rate of 75 rpm, the DNG and the EE, respectively, exhibit a dissolution profile wherein:
(i) no more than 25% of the DNG and no more than 25% of the EE initially present in the composition is dissolved within 1 hour;
(ii) between 30% and 55% of the DNG and between 30% and 55% of the EE initially present in the composition is dissolved within 2 hours; and
(iii) at least 80% of the DNG and at least 80% of the EE initially present in the composition is dissolved within 5 hours.
13. The contraceptive composition according to claim 1 , wherein, after once daily oral administration to human premenopausal female under fasting conditions for 7 days, the oral contraceptive composition provides:
a Cmax of EE of about 63.6 pg/mL;
a Tmax of EE of about 3.75 hours;
an AUC 0-24 hr of EE of about 706.3 pgxh/mL;
a Cmax of DNG of about 59.3 ng/ml;
a Tmax of DNG of about 3.75 hours; and
an AUC 0-24 hr of DNG of about 731.6 ngxh/mL.
14. The contraceptive composition according to claim 1 , wherein the composition is formulated for administration as a daily active oral form in a contraceptive regimen comprising administration of the daily active oral form for 21 to 24 consecutive days followed by a period of 4 to 7 days of daily administration of a placebo oral form or no oral form administration.
15. The contraceptive composition according to claim 14 , wherein the contraceptive regimen comprises administration of the daily active oral form for 24 consecutive days followed by a period of 4 days of daily administration of a placebo oral form.
16. The contraceptive composition according to claim 1 , wherein the tablet is a film-coated tablet.
17. The contraceptive composition according to claim 16 , wherein the film coating of the film-coated tablet comprises a polymer, a plasticizer and a pigment.
18. The contraceptive composition according to claim 17 , wherein the polymer comprises a polyethylene glycol.
19. The contraceptive composition according to claim 17 , wherein the polymer comprises a polyethylene glycol having an average molecular weight within 5,000-7,000 Daltons.
20. A contraceptive kit, comprising one or more packaging units wherein each packaging unit comprises at least 21 to 24 oral contraceptive compositions according to claim 1 as daily active dosage forms and at least 4 to 7 daily placebo dosage forms.
21. The contraceptive kit of claim 20 , wherein each packaging unit comprises 24 of the oral contraceptive compositions as daily active dosage forms and 4 of the daily placebo dosage forms.
22. A method for oral contraception in a female subject in need thereof, the method comprising:
(i) a first phase wherein active daily dosage units of the oral contraceptive composition of claim 1 are administered to the female subject over a period of 21 to 27 consecutive days; and
(ii) a second phase wherein no contraceptive composition is administered to the female subject over a period of 1 to 7 consecutive days.
23. The method of claim 22 , wherein the first phase lasts from 21 to 24 consecutive days, and the second phase lasts from 4 to 7 consecutive days.
24. The method of claim 22 , wherein the first phase lasts 24 consecutive days, and the second phase lasts 4 consecutive days.